Insight Molecular Diagnostics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
27.8%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$2.5Mnext fiscal year
FY EPS (est.)
-$0.85next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
GraftAssureDx FDA Regulatory Review Status QuarterlyTarget: FDA De Novo Marketing Authorization
Transplant Center Engagement Count (U.S.) Quarterly37Target: Expand registry trial to 28 active sites and scale commercial accounts
Quarterly Cash Burn Rate Quarterly9MTarget: Reduce to $6 million per quarter in H2 2026
Quarterly Revenue Quarterly32KTarget: Projected $250,000 in Q2 2026
Watch Items
- FDA De Novo review timeline for GraftAssureDxTrigger: 150-day standard review clock stops or requests for additional analytical dataAction: Assess impact on the expected late-2026 commercial launch and adjust cash runway projections.
- Cash runway and burn rate managementTrigger: Quarterly cash burn exceeding $9 million in H2 2026Action: Evaluate potential dilutive financing options or strategic restructuring to preserve capital.
- Commercial adoption of GraftAssure kitted assaysTrigger: U.S. transplant center registry participation drops below 25% of annual transplantsAction: Re-evaluate sales and marketing strategy, and leverage peer-reviewed clinical data to drive clinical switching.
Research as of 20 Jun 2026